Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.42 |
| ▸ | EBP | Q15125 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26118274 | 1.00 | KDM4E (0.47) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| SCHEMBL14175056 | 0.97 | KDM4E (0.47) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| SCHEMBL19853574 | 0.97 | KDM4E (0.47) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| SCHEMBL18411956 | 0.94 | KDM4E (0.48) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| Cyanide SCHEMBL27977140 | 0.92 | KDM4E (0.43) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| SCHEMBL12718121 | 0.89 | KDM4E (0.46) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| SCHEMBL21931367 | 0.89 | KDM4E (0.47) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| SCHEMBL803892 | 0.88 | KDM4E (0.44) | KDM4EPOLBALDH1A1DHCR7EBP | |
| SCHEMBL763685 | 0.88 | KDM4E (0.44) | KDM4EPOLBALDH1A1ALOX15DHCR7 | |
| SCHEMBL18976856 | 0.88 | KDM4E (0.53) | KDM4EPOLBALDH1A1ALOX15DHCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015055-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4230624-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | The Asan Foundation (KR) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023150291-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023064880-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022192598-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022166920-A1 | PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022113003-A1 | CDK INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005032490-A2 | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | KDM4E 1327/4885POLB 4215/4885ALDH1A1 2753/4885 |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | KDM4E 4187/4885POLB 4652/4885ALDH1A1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.